On the public citation graph
Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
0 signed · 19 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1056/nejmoa1505270openalex-snapshot
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1607303openalex-snapshot
Palbociclib and Letrozole in Advanced Breast Cancer
inferredcites →https://doi.org/10.1111/cas.12932openalex-snapshot
Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
inferredcites →https://doi.org/10.1111/cas.13507openalex-snapshot
Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0754openalex-snapshot
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1535-7163.1427.3.11openalex-snapshot
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
inferredcites →https://doi.org/10.1200/jco.2017.73.7585openalex-snapshot
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
inferredcites →https://doi.org/10.1200/jco.2017.75.6155openalex-snapshot
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
inferredcites →https://doi.org/10.1634/theoncologist.2017-0072openalex-snapshot
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4765196openalex-extracted
Discovery and Preclinical Evaluations of Tqb3616, a Novel Cdk4-Biased Inhibitor
inferred← citeshttps://doi.org/10.1007/s10147-021-02013-8openalex-snapshot
Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.129769openalex-snapshot
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
inferred← citeshttps://doi.org/10.1016/j.isci.2022.104752openalex-snapshot
Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
inferred← citeshttps://doi.org/10.1080/14740338.2024.2387323openalex-snapshot
A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1080/14756366.2024.2418470openalex-snapshot
Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation
inferred← citeshttps://doi.org/10.1177/1178223420983843openalex-snapshot
Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study
inferred← citeshttps://doi.org/10.1248/bpb.b22-00338openalex-snapshot
The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels
inferred← citeshttps://doi.org/10.2147/cmar.s348591openalex-snapshot
Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.